{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T20:39:18Z","timestamp":1758400758986,"version":"3.44.0"},"reference-count":10,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["jidonline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Investigative Dermatology"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.jid.2020.03.977","type":"journal-article","created":{"date-parts":[[2020,6,22]],"date-time":"2020-06-22T05:14:12Z","timestamp":1592802852000},"page":"429-431","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["The Importance of Methodological Rigor in Proof-of-Concept Clinical Trials: A Lesson from Hidradenitis Suppurativa"],"prefix":"10.1016","volume":"141","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3305-3814","authenticated-orcid":false,"given":"Kelsey R.","family":"van Straalen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5042-3632","authenticated-orcid":false,"given":"John W.","family":"Frew","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jid.2020.03.977_bib1","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1016\/j.jaad.2020.02.005","article-title":"Secukinumab in the treatment of moderate to severe hidradenitis suppurativa: results of an open-label trial","volume":"82","author":"Casseres","year":"2020","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jid.2020.03.977_bib2","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1016\/j.jaad.2019.12.044","article-title":"Clinical response rates, placebo response rates and significantly associated covariates are dependent upon choice of outcome measure in hidradenitis suppurativa: a post-hoc analysis of pioneer 1 and 2 individual patient data","volume":"82","author":"Frew","year":"2020","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jid.2020.03.977_bib3","doi-asserted-by":"crossref","DOI":"10.1111\/bjd.18877","article-title":"Clinical efficacy of complement c5a inhibition by ifx-1 in hidradenitis suppurativa: an open-label single-arm trial in patients not eligible for adalimumab [e-pub\u00a0ahead of print]","author":"Giamarellos-Bourboulis","year":"2020","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2020.03.977_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.jid.2019.10.024","article-title":"A\u00a0phase II, open-label study of bermekimab in patients with hidradenitis suppurativa shows resolution of inflammatory lesions and pain [e-pub ahead of print]","author":"Gottlieb","year":"2020","journal-title":"J\u00a0Invest Dermatol"},{"year":"2019","series-title":"07\u20132019-InflaRx reports additional analysis of the SHINE Phase IIb results for IFX-1 in hidradenitis suppurativa","key":"10.1016\/j.jid.2020.03.977_bib5"},{"key":"10.1016\/j.jid.2020.03.977_bib6","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.jid.2017.10.030","article-title":"MABp1 targeting IL-1\u03b1 for moderate to severe hidradenitis suppurativa not eligible for adalimumab: a randomized study","volume":"138","author":"Kanni","year":"2018","journal-title":"J\u00a0Invest Dermatol"},{"year":"2010","series-title":"The prevention and treatment of missing data in clinical trials","key":"10.1016\/j.jid.2020.03.977_bib7"},{"key":"10.1016\/j.jid.2020.03.977_bib8","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1111\/bjd.16672","article-title":"A\u00a0core domain set for hidradenitis suppurativa trial outcomes: an international Delphi process","volume":"179","author":"Thorlacius","year":"2018","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2020.03.977_bib9","article-title":"Current and future treatment of hidradenitis suppurativa [e-pub ahead of print]","author":"van Straalen","year":"2018","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2020.03.977_bib10","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jaad.2018.05.040","article-title":"Long-term adalimumab efficacy in patients with moderate-to-severe hidradenitis suppurativa\/acne inversa: 3-year results of a phase 3 open-label extension study","volume":"80","author":"Zouboulis","year":"2019","journal-title":"J\u00a0Am Acad Dermatol"}],"container-title":["Journal of Investigative Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X20316869?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X20316869?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T17:21:35Z","timestamp":1758302495000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022202X20316869"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":10,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["S0022202X20316869"],"URL":"https:\/\/doi.org\/10.1016\/j.jid.2020.03.977","relation":{},"ISSN":["0022-202X"],"issn-type":[{"type":"print","value":"0022-202X"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Importance of Methodological Rigor in Proof-of-Concept Clinical Trials: A Lesson from Hidradenitis Suppurativa","name":"articletitle","label":"Article Title"},{"value":"Journal of Investigative Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jid.2020.03.977","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.jid.2019.10.024","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier, Inc. on behalf of the Society for Investigative Dermatology.","name":"copyright","label":"Copyright"}]}}